EOLS - Evolus, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $15.00 DETAILS

Stock News

Evolus to Participate in The Jefferies Global Healthcare Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Jefferies Global Healthcare Conference in New York City. The fireside chat will take place on Thursday, June 4th, 2026, at 12:50 PM ET. The fireside chat can be accessed on the Investor Relations page of the Evol.

May 19, 2026 04:30 AM • businesswire.com

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the commercial launch of Estyme® (pronounced “esteem”), its injectable hyaluronic acid (HA) gel collection in Europe, is scheduled for May 16th, marking the company's entry into the international dermal filler market. The Estyme® collection includes four injectable HA gels that will cover a wide range of.

May 11, 2026 04:30 AM • businesswire.com

Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript

May 04, 2026 10:13 PM • seekingalpha.com

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago.

May 04, 2026 04:30 PM • zacks.com

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the first quarter ended March 31, 2026. “We started 2026 with a second consecutive quarter of positive Adjusted EBITDA, delivering profitability1 in what is seasonally our lowest revenue quarter,” said David Moatazedi, President and Chief Executive Officer of Evolus. “This performanc.

May 04, 2026 12:05 PM • businesswire.com

Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference

Evolus (NASDAQ: EOLS) executives told investors at Needham and Company's 25th Annual Healthcare Conference that the company is pursuing double-digit growth and a transition to full-year profitability as it expands beyond its flagship neurotoxin Jeuveau and scales its newer hyaluronic acid (HA) filler line, Evolysse. In a fireside chat moderated by Needham healthcare analyst Serge Belanger,

Apr 17, 2026 12:02 AM • defenseworld.net

Evolus to Report First Quarter Financial Results on May 4, 2026

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2026 financial results on Monday, May 4, 2026, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To partic.

Apr 14, 2026 04:30 AM • businesswire.com

JPMorgan Chase & Co. Decreases Stake in Evolus, Inc. $EOLS

JPMorgan Chase and Co. decreased its holdings in Evolus, Inc. (NASDAQ: EOLS) by 35.5% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 446,311 shares of the company's stock after selling 246,175 shares during the quarter. JPMorgan Chase and Co. owned about 0.69%

Apr 06, 2026 12:45 AM • defenseworld.net

Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Virtual Healthcare Conference. The fireside chat will take place on Tuesday, April 14, 2026, at 3:45 PM ET. The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A r.

Mar 31, 2026 04:00 AM • businesswire.com

Evolus (NASDAQ:EOLS) Insider Sells $14,815.25 in Stock

Evolus, Inc. (NASDAQ: EOLS - Get Free Report) insider Rui Avelar sold 3,119 shares of the firm's stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $4.75, for a total transaction of $14,815.25. Following the transaction, the insider directly owned 427,423 shares in the company, valued

Mar 23, 2026 01:26 AM • defenseworld.net

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS) a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during March 2026 of an aggregate of 85,516 restricted stock units (RSUs) and 8,635 stock options of the company's common stock to 10 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducemen.

Mar 20, 2026 12:05 PM • businesswire.com

Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference

Evolus (NASDAQ: EOLS) executives said they are seeing signs of stabilization and improvement in the U.S. botulinum toxin market after a period of industry-wide pressure, while describing a slower recovery for dermal fillers amid changing consumer sentiment. Speaking at the Leerink Conference, CEO David Moatazedi, CFO Tatjana Mitchell, and Head of R&D Rui Avelar also outlined

Mar 16, 2026 10:32 PM • defenseworld.net

Evolus, Inc. (NASDAQ:EOLS) Receives $17.50 Average Target Price from Analysts

Shares of Evolus, Inc. (NASDAQ: EOLS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the

Mar 04, 2026 08:10 PM • defenseworld.net

Why Evolus Stock Soared Today

Demand for Evolus' beauty products is growing. Management expects to generate sustainable profits in 2026.

Mar 04, 2026 05:45 PM • fool.com

Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript

Mar 03, 2026 09:42 PM • seekingalpha.com

Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates

Evolus, Inc. (EOLS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.01 per share a year ago.

Mar 03, 2026 02:06 PM • zacks.com

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the fourth quarter and full-year ended December 31, 2025. “In 2025 we generated nearly $300 million in total net revenue delivering our sixth consecutive year of double-digit growth,” said David Moatazedi, President and Chief Executive Officer of Evolus. “Our performance beauty posit.

Mar 03, 2026 11:05 AM • businesswire.com

Evolus to Participate in The Leerink Partners Global Healthcare Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Leerink Partners Global Healthcare Conference in Miami, FL. The fireside chat will take place on Wednesday, March 11, 2026, at 11:20 AM ET. The fireside chat can be accessed on the Investor Relations page of the.

Feb 25, 2026 03:00 AM • businesswire.com

Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Feb 24, 2026 06:01 AM • zacks.com

Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's.

Feb 17, 2026 03:00 AM • businesswire.com

Price Targets